We are headed for $10 million year-end revenue (2015) -over 100% over prior year.
Review of selection financial doc's just released by HEMA.
Brief mention about VSYM merger and Biotech ARWR
SO AS TO KEEP UP WITH THE CONTINUAL CHANGING INTERACTIVE AS WELL AS CHANGING SOCIAL MEDIA WE HAVE DECIDED TO INTRODUCE TO OUR SUBSCRIBER BASE A "TWITTER" RELEASE FORMAT THAT THOSE INVESTOR'S THAT WANT IT "FIRST" REALIZE IT COSTS TO BE FIRST INLINE !
Hemacare HEMA~~ .37
Recall that we recently recommended HEMA on Sept 15, 2015. (see last email alert)
We thought that Dec 2014 year-end numbers and the first 6 months of 2015 would not be released until some time during the month of Oct 2015.
Numbers were released today and the results indicate a very strong growth picture and a very robust balance sheet.
Year-ending Dec 2014
(Business is only from new business model- Blood & Bioresearch products)
Revenue $4.8 million
loss from operations $4.7 million
gain from discontinued operations $1.2 million
net loss- $3.5 million
book value- $2 million or around .19
shares outstanding 10.7 million
NOL $10.2 million fed and $7 million state
This NOL is worth almost $1.00/sh- huge benefit and could be used to attract acquisition or merger.
Current share buyback program still viable for the purchase of 2 million shares.
Audit complete for first 6 months of 2015 ending June 30th 2015
Revenue -$4.3 million
loss from operations $820k
Cash $2.6 million
NOTE: Upon review of year-end Doc -page 11 note 3 it appears that (2014 filing located on Hemacare website) that HEMA may be entitled to additional money from the final sale of Apheresis Division- as of August 10, 2015 (this filing doesn't include of June 30th 2015 filing)
Book value as of June 30th- $5.4 million or around .50
We are even more Bullish toward this issue than prior recommendation because of early filing and better than anticipated results and balance sheet.
At this point in time we believe that HEMA can and will deliver revenue for 2015 of around $10 million and may even show a profit for the second half of 2015.
The company has zero debt and attractive cash horde. Upon reading the press release date Sept 21, 2015 management "crows" that this company is rapidly growing and has had excellent success in penetrating the growth of cell therapy market.
If HEMA had Wall Street eyeballs- It is in our opinion that HEMA could and would be trading @ 10x the current price.
We remain extremely Bullish toward HEMA and truly anticipate that the current share price will resonate in the near term when "I could have and should have!"
Believe me, if this stock was running, the herd would fall over one another, but since it has limited trading- average investors sit and spin around !
Finally --- go too the HEMA website- there updated site is very informative and the news is current. See recent press of a few days ago.
Strong Buy rating at current levels with strong upside potential near term and long term.
VSYM -See earlier recommendation dated July 1, 2015. We have heard via the grape vine that a merger agreement is going to be announced within days.
We remain committed to this sub-penny issue and believe that VSYM will make a positive move based upon the merger and the potential of an acquisition. This appears as a classic roll-up. Please recall that VSYM is fully reporting with a huge NOL that can be very attractive for growth oriented companies.
We know that VSYM is only trading @ .005/share, but this company has state-of-art products & intends to increase awareness and this will be done by merging and acquiring and then raise some cash.
ARWR-- The AD day is on the 24th of Sept and we will live by the sword or die by the sword!
All we can say is why rent a hotel conference space to announce bad news and why would you invite noted speakers!
Do you think that this was just an excuse to visit the 9-11 memorial so as to write off the trip? We doubt it!
As mentioned there is a CT filing that was filed around 45 days ago and has not been made public.
As mentioned, GILD has made 2 bids for this company during the past couple of years & ARWR has declined the offer to be bought out! We believe that if the news on their Phase 2 trials on the chimps are successful that this CT form could very well yield an announcement of a huge cash infusion, which will make ARWR fly!
As mentioned we believe that the stock trades after the meeting @ $4.00 or $15.00 plus. Choose the right Scotch!
NEW SERVICE OFFERED TO S A ADVISORY SUBSCRIBERS
FOR $150.00/YR WE WILL ALLOW YOU TO BECOME A FOLLOWER AND WILL "TWEET" YOU ALL DOC'S AND RECOMMENDATIONS BEFORE THE EMAIL HERD GETS THEM.
THIS WILL INCLUDE ARTICLE OF INTERESTS, TRENDS AND OF COURSE THE CURRENT NEW RECOMMENDATION AND ACTIVE NEWS ON THAT SPECIFIC RECOMMENDATION!
SEND CHECK FOR $150.00 TO OUR SALT LAKE CITY ADDRESS AND WE WILL SUPPLY YOU WITH OUR "HANDLE" SO YOU RECEIVE EVERYTHING THAT WE BELIEVE IS IMPORTANT AND THE LATEST RECOMMENDATION
WE CALL THIS PRIORITY INVESTING!!
S A ADVISORY, 4700 S HOLLADAY BLVD
S L C , UTAH 84117
MAKE SURE YOU INCLUDE YOUR PHONE NUMBER SO AS WE CAN GIVE YOU MY PERSONAL HANDLE.
Any questions- call 801 272 4761 or 949 922 9986
Global cooling is coming soon to your city. Believe it or not- we ride a life-cycle between 125-180 miles/week as a pre-season preparation for the global cooling season!